Baxter International Inc. (BAX)
| Market Cap | 9.29B -40.3% |
| Revenue (ttm) | 11.32B +5.1% |
| Net Income | -1.10B |
| EPS | -2.14 |
| Shares Out | 516.47M |
| PE Ratio | n/a |
| Forward PE | 9.07 |
| Dividend | $0.04 (0.22%) |
| Ex-Dividend Date | May 29, 2026 |
| Volume | 7,865,855 |
| Open | 17.71 |
| Previous Close | 17.49 |
| Day's Range | 17.29 - 18.00 |
| 52-Week Range | 15.73 - 32.68 |
| Beta | 0.62 |
| Analysts | Hold |
| Price Target | 21.25 (+18.12%) |
| Earnings Date | Apr 30, 2026 |
About BAX
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies;... [Read more]
Financial Performance
In 2025, Baxter International's revenue was $11.24 billion, an increase of 5.72% compared to the previous year's $10.64 billion. Losses were -$957.00 million, 47.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for BAX stock is "Hold." The 12-month stock price target is $21.25, which is an increase of 18.12% from the latest price.
News
Baxter International Transcript: AGM 2026
The meeting covered board updates, five key proposals, and voting outcomes. All proposals, including director elections, executive compensation, auditor ratification, incentive plan, and board size amendment, were approved by strong majorities. Final results will be filed on Form 8-K.
Baxter price target raised to $27 from $25 at Barclays
Barclays raised the firm’s price target on Baxter (BAX) to $27 from $25 and keeps an Overweight rating on the shares. The comapny surprised investors expecting a guidance cut with
Baxter price target lowered to $17 from $19 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Baxter (BAX) to $17 from $19 and keeps a Neutral rating on the shares. Baxter’s Q1 results reflected ongoing operational and margin
Baxter International Earnings Call Transcript: Q1 2026
First quarter results were in line with expectations, with reported sales up 3% but organic sales down 1% and adjusted EPS down 35% year-over-year. Guidance for 2026 is reiterated, with flat organic sales and improved performance expected in the second half, supported by new product launches and operational improvements.
Baxter beats quarterly expectations on strong demand for medical devices
Baxter on Thursday beat Wall Street estimates for first-quarter profit and revenue, helped by robust sales in its medical products and therapies unit.
Baxter Reports First-Quarter 2026 Results
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX), a global medtech leader, today reported results for the first quarter of 2026. “Financial results for the quarter overall were ...
Baxter showcases Global Surgical Solutions portfolio at AORN Conference
Baxter (BAX) International is highlighting recent additions to its Global Surgical Solutions and Patient Support Systems portfolios, as well as its broad Advanced Surgery portfolio of hemostatic and s...
Baxter Showcases Recent Innovations at AORN Global Surgical Conference & Expo 2026
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, is highlighting recent additions to its Global Surgical Solutions and Patient Support Systems portfolio...
Baxter to Host First-Quarter 2026 Financial Results Conference Call for Investors
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its first-quarter 2026 financial results on Thursday, A...
Baxter price target lowered to $22 from $23 at Evercore ISI
Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Baxter (BAX) to $22 from $23 and keeps an Outperform rating on the shares as part of the firm’s
Baxter introduces IV Verify Line Labeling System
Baxter (BAX) International debuted the IV Verify Line Labeling System, an automated solution, at the 2026 American Organization for Nursing Leadership Conference. The IV Verify system is designed to s...
Baxter Introduces the IV Verify Line Labeling System, an Automated Solution to Improve IV Labeling in Healthcare Settings
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and platforms, today debuted the IV Verify Line Labeling System, an automated solutio...
Baxter to Host Annual Meeting of Stockholders in Virtual Format
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2026 Annual Meeting) in a virtual format on Tuesday, ...
Pet Partners and the Baxter Foundation Expand Therapy Animal Programs to Support 100,000 Patients and Healthcare Workers in Two-Year Pilot
Largest Single Investment from a Corporate Foundation Aims to Strengthen Healthcare Resilience by Advancing Therapy Animal Visits in U.S. Healthcare Settings BELLEVUE, Wash. and DEERFIELD, Ill.
EU regulator warns of shortage in Baxter's cancer treatment until early 2027
The European Union's medicines regulator said on Tuesday it expects Baxter International's cancer drugs containing ifosfamide will remain in shortage in the bloc well into the first quarter of next ...
Baxter CFO Joel Grade to depart
Baxter (BAX) announced the departure of executive vice president and chief financial officer Joel Grade. Grade is leaving the company to prioritize family matters but will continue in an advisory
Baxter backs FY26 adjusted EPS view $1.85-$2.05, consensus $1.92
Backs FY26 revenue view flat to up 1%. Backs FY26 organic sales view approximately flat. The company said, “Baxter (BAX) also announced today that the company is reiterating its full-year
Baxter Announces CFO Transition
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the departure of executive vice president and chief financial officer (CFO) Joel Grade....
Baxter International Transcript: Barclays 28th Annual Global Healthcare Conference
Middle East exposure is minimal and oil price sensitivity has dropped by over half since 2022, mainly due to business divestitures and delivery model changes. New leadership and operating models are driving efficiency, while Advanced Surgery and HST show strong performance. Margin recovery is expected in the second half of the year.
Baxter price target lowered to $19 from $21 at Citi
Citi lowered the firm’s price target on Baxter (BAX) to $19 from $21 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical technology group
Baxter International Transcript: Citi’s 2026 Unplugged MedTech and Life Sciences Access Day
Medtech fundamentals are stable, with new leadership driving operational consistency and innovation. Guidance for 2026 is prudent, reflecting a new baseline in IV solutions, ongoing Novum pump ship hold, and a focus on deleveraging and margin improvement.
Baxter price target lowered to $17 from $21 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Baxter (BAX) to $17 from $21 and keeps a Neutral rating on the shares. The company’s results and 2026 outlook generally fell
Baxter price target lowered to $19 from $21 at UBS
UBS analyst Danielle Antalffy lowered the firm’s price target on Baxter (BAX) to $19 from $21 and keeps a Neutral rating on the shares. The firm sees limited near-term visibility
Baxter price target lowered to $20 from $22 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Baxter (BAX) to $20 from $22 and keeps a Hold rating on the shares.